PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation

References

• Alexopoulou E, Georgopoulos A, Kagkadis KA, et al. (2006). Preparation and characterization of lyophilized liposomes with incorporated quercetin. J Liposome Res 16:17–25
   PubMed Web of Science ®Google Scholar
• Arica B, Ozer AY, Ercan MT, et al. (1995). Characterization, in vitro and in vivo studies on primaquine diphosphate liposomes. J Microencapsul 12:469–85
   PubMed Web of Science ®Google Scholar
• Atyabi F, Farkhondehfai A, Esmaeili F, Dinarvand R. (2009). Preparation of PEGylatednano-liposomal formulation containing SN-38: in vitro characterization and in vivo biodistribution in mice. Acta Pharm 59:133–44
   PubMed Web of Science ®Google Scholar
• Azmin MN, Florence AT, Handjani RM, et al. (1985). The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol 37:237–42
   PubMed Web of Science ®Google Scholar
• Bangham AD, Horne RW (1964). A correlation between surface charge and coagulant action of phospholipids. J Mol Biol 8:660–8
   PubMed Web of Science ®Google Scholar
• Bangham AD, Standish MM, Watkins JC. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:297–328
   Google Scholar
• Betageri GV, Parsons DL. (1992). Drug encapsulation and release from multilamellar and unilamellar liposomes. Int J Pharm 81:235–41
   Web of Science ®Google Scholar
• Bhalerao SS, Harshal AR. (2003). Preparation, optimization, characterization and stability studies of salicyclic acid liposomes. Drug Dev Ind Pharm 29:457–67
   Google Scholar
• Boddé HE, Joosten JGH. (2006). A mathematical model for drug release from a two-phase system to a perfect sink. Int J Pharm 26:57–76
   Google Scholar
• Carstensen JT. (1995). Drug stability: principles and practices. Vol, 68. 2nd ed. New York: Marcel Dekker, 538–50
   Google Scholar
• Chen C, Gang L, Pan C, et al. (2007). Poly (lactic acid) (PLA) based nanocomposites – a novel way of drug-releasing. Biomed Mater 2:L1–4
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu Y, Chen J, et al. (2009). Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm 376:153–60
   PubMed Web of Science ®Google Scholar
• Coleman MP, Quaresma M, Berrino F, et al. (2008). Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9:730–56
   PubMed Web of Science ®Google Scholar
• Crommelin DJA, Daemen T, Scherphof GL, et al. (1997). Liposomes: vehicles for the targeted and controlled delivery of peptides and proteins. J Control Release 46:165–75
   Web of Science ®Google Scholar
• Crosasso P, Ceruti M, Brusa P, et al. (2000). Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release 63:19–30
   PubMed Web of Science ®Google Scholar
• Deol P, Khuller GK. (1997). Lung specific stealth liposomes: stability biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochem Biophys Acta 1334:161–72
   PubMed Web of Science ®Google Scholar
• Deshpande PB, Dandagi P, Udupa N, et al. (2010). Controlled release polymeric ocular delivery of acyclovir. Pharm Dev Technol 15:369–78
   PubMed Web of Science ®Google Scholar
• Dodov MG, Kumbaradì EF, Calis S, et al. (2004). Formulation and characterization of 5-flurouracil loaded liposomes. Bull Chem Technol Macedonia 23:13–18
   Google Scholar
• Drummond DC, Meyer O, Hong K, et al. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 4:691–743
   Google Scholar
• Dubey V, Mishra D, Jain NK. (2007). Melatonin loaded ethanolic liposomes: physicochemical characterization and enhanced transdermal delivery. Eur J Pharm Biopharm 67:398–405
   PubMed Web of Science ®Google Scholar
• Elron-Gross I, Glucksam Y, Margalit R. (2009). Liposomal dexamethasone–diclofenac combinations for local osteoarthritis treatment. Int J Pharm 376:84–91
   PubMed Web of Science ®Google Scholar
• Fetterly GJ, Straubinger RM. (2003). Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS Pharm Sci 5:1–11
   Google Scholar
• Gopal VS, Usha YN, Sreenivasa Reddy M, et al. (2011). Sustained release optimized formulation of anastrozole-loaded chitosan microspheres: in vitro and in vivo evaluation. J Mater Sci Mater Med 22:865–78
   PubMed Web of Science ®Google Scholar
• Gu XQ, Ma ZQ, Li HQ, et al. (1982). Study on the polyphase liposomes – a new dosage form for antitumor drugs. Antitumor activity screening of polyphase liposome 139 and others. Clin Herb Med 13:13–19
   Google Scholar
• Guo JX, Ping QN, Dong J, et al. (2005). Mechanisms of action of transportation of liposomes and chitosan-coated liposomes containing leuprolide across intestine and Caco-2 cell. Acta Pharm Sinica 40:65–70
   Google Scholar
• Hashizaki K, Taguchi H, Itoh C, et al. (2003). Effects of poly(ethylene glycol) (PEG) chain length of PEG-lipid on the permeability of liposomal bilayer membranes. Chem Pharm Bull 51:815–20
   PubMed Web of Science ®Google Scholar
• Hathout RM, Mansour S, Mortada ND, Guinedi AS. (2007). Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech 8:1
   PubMed Web of Science ®Google Scholar
• Hinrichs WL, Manceñido FA, Sanders NN, et al. (2006). The choice of a suitable oligosaccharide to prevent aggregation of PEGylated nanoparticles during freeze thawing and freeze drying. Int J Pharm 311:237–44
   PubMed Web of Science ®Google Scholar
• ICH Q1A (R2) (2003). Stability testing of new drug substances and products. International Conference on Harmonization. U.S. Department of Health and Human Service Food and Drug Administration
   Google Scholar
• Immordino ML, Brusa P, Arpicco S, et al. (2003). Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release 91:417–29
   PubMed Web of Science ®Google Scholar
• Jain SK, Jain NK. (1997). Liposomes as drug carriers. In: Jain NK, ed. Controlled and novel drug delivery. 1st ed. New Delhi: CBS Publishers, 304–52
   Google Scholar
• Jain SK, Jain RK, Chourasia MK, et al. (2005). Design and development of multivesicular liposomal depot delivery: system for controlled systemic delivery of acyclovir sodium. AAPS PharmSciTech 6:E35–41
   PubMed Web of Science ®Google Scholar
• Jain A, Sanghvi T, Samue HY. (2003). Liposome formulation of NSC-639829 using halothane as a solvent: a technical note. AAPS PharmSciTech 4:E52
   PubMedGoogle Scholar
• Junping W, Maitani Y, Takayama K, et al. (2000). In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome. Int J Pharm 203:61–9
   PubMed Web of Science ®Google Scholar
• Kaiser N, Kimpfler A, Massing U, et al. (2003). 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties. Int J Pharm 256:123–31
   PubMed Web of Science ®Google Scholar
• Kim HS, Song IH, Kim JC, et al. (2006). In vitro and in vivo gene-transferring characteristics of novel cationic lipids, DMKD (O,O′-dimyristyl-N-lysyl aspartate) and DMKE (O,O′-dimyristyl-N-lysyl glutamate). J Control Release 115:234–41
   PubMed Web of Science ®Google Scholar
• Liu F, Chen Z, Wang J, et al. (2008). Over expression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia 10:1275–84
   Google Scholar
• Momo F, Fabris S, Stevanat R. (2005). Interaction of fluoxetine with phosphatidylcholine liposomes. Biophys Chem 118:15–21
   PubMed Web of Science ®Google Scholar
• Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
   PubMed Web of Science ®Google Scholar
• Musteata FM, Pawliszyn J. (2006). Determination of free concentration of paclitaxel in liposome formulations. J Pharm Pharm Sci 9:231–7
   PubMed Web of Science ®Google Scholar
• Nabholtz JM. (2006). Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention. Oncology 70:1–12
   PubMed Web of Science ®Google Scholar
• Nabholtz JMA. (2008). Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther Clin Risk Manage 4:189–204
   PubMedGoogle Scholar
• Nabholtz JM, Buzdar A, Pollak M, et al. (2000). Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex study group. J Clin Oncol 18:3758–67
   PubMed Web of Science ®Google Scholar
• Nicholov R, Ditizio V, Dicosmo F. (1995). Interaction of paclitaxel with phospholipid bilayers. J Liposome Res 5:503–22
   Google Scholar
• Nicolini A, Giardino R, Carpi A, et al. (2006) Metastatic breast cancer: an updating. Biomed Pharmacother 60:548–56
   PubMed Web of Science ®Google Scholar
• Nounou MM, El-Khordagui LK, Khalafallah NA, Khalil SA. (2006). In vitro release of hydrophilic and hydrophobic drugs from liposomal dispersions and gels. Acta Pharm 56:311–24
   PubMedGoogle Scholar
• Park YS. (2002). Tumor-directed targeting of liposomes. Biosci Rep 22:267–81
   PubMed Web of Science ®Google Scholar
• Patel PA, Patil SC, Kalaria DR, et al. (2013). Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A. Int J Pharm 446:16–23
   PubMed Web of Science ®Google Scholar
• Sargent JM. (2003). The use of the MTT assay to study drug resistance in fresh tumour samples. Recent Results Cancer Res 161:13–25
   PubMedGoogle Scholar
• Sarkar K, Yang H. (2008). Encapsulation and extended release of anti-cancer anastrozole by stealth nanoparticles. Drug Deliv 15:343–6
   PubMed Web of Science ®Google Scholar
• Schliecker G, Schmidt C, Fuchs S, et al. (2004). In vitro and in vivo correlation of buserelin release from biodegradable implants using statistical moment analysis. J Control Release 94:25–37
   PubMed Web of Science ®Google Scholar
• Schnyer A, Huwyler J. (2005). Drug transport to brain with targeted liposomes. J Am Soc Exp Neurother 2:99–107
   Google Scholar
• Sezer AD, Bas AL, Akbuga J. (2004). Encapsulation of Enrofloxacin in liposomes: Preparation and in vitro characterization. J Liposome Res 14:77–86
   PubMed Web of Science ®Google Scholar
• Shah SP, Misra A. (2004). Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. AAPS PharmSciTech 5:1–7
   Google Scholar
• Srinath P, Chary MG, Vyas SP, et al. (2000). Long-circulating liposomes of indomethacin in arthritic rats – a biodisposition study. J Control Release 74:399–404
   Google Scholar
• Thomas RJ, Williams M, Glen J, Callam M. (2009). Comparing the cost of adjuvant Anastrozole with the benefits of managing less patients with relapsed breast cancer. Breast Cancer Res Treat 7:289–95
   Google Scholar
• Tianshun L, Rodney JY. (2001). Trends and developments in liposome drug delivery systems. J Pharm Sci 90:667–80
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Trubetskoy VS. (1995). Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev 16:141–55
   Web of Science ®Google Scholar
• Turanek J, Wang XF, Knotigova P. (2009). Liposomal formulation of alpha-tocopherylmaleamide: in vitro and in vivo toxicological profile and anticancer effect against spontaneous breast carcinomas in mice. Toxicol Appl Pharmacol 237:249–57
   PubMed Web of Science ®Google Scholar
• Wiseman LR, Adkins JC. (1998). Anastrozole: a review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging 4:321–32
   Google Scholar
• World Health Organization (2008). The global burden of disease: 2004 update. Geneva, Switzerland: WHO Press, World Health Organization
   Google Scholar
• Yang T, Choi MK, Cui FD, et al. (2007a). Antitumor effect of paclitaxel-loaded PEGylated immune liposomes against human breast cancer cells. Pharm Res 24:2402–11
   PubMed Web of Science ®Google Scholar
• Yang T, Cui FD, Choi MK, et al. (2007b). Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm 338:317–26
   PubMed Web of Science ®Google Scholar
• Yang T, Koo M, Cui CFD, et al. (2007c). Preparation and evaluation of paclitaxel-loaded PEGylated immuno liposomes. J Control Release 120:169–77
   PubMed Web of Science ®Google Scholar
• Yang X, Zhao X, Phelpsa MA, et al (2009). A novel liposomal formulation of flavopiridol. Int J Pharm 365:170–4
   PubMed Web of Science ®Google Scholar
• Zhang JA, Anyarambhatla G, Ma L, et al. (2005). Development and characterization of a novel cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 59:177–87
   PubMed Web of Science ®Google Scholar
• Zhao L, Wei YM, Zhong XD, et al. (2009). PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. J Pharm Biomed Anal 49:989–96
   PubMed Web of Science ®Google Scholar